Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving oxidoreductase
Reexamination Certificate
2005-08-15
2008-07-08
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving oxidoreductase
C435S069200, C514S866000
Reexamination Certificate
active
07396659
ABSTRACT:
A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a biologically effective amount of at least one inhibitor of inducible nitric oxide synthase or a pro-inflammatory cytokine, wherein the inhibitor is an inhibitor of HMG-CoA reductase or a pharmaceutically acceptable salt thereof, and the inhibitor specifically inhibits the activity of HMG-CoA reductase.
REFERENCES:
patent: 5118601 (1992-06-01), Gruber
patent: 5130333 (1992-07-01), Pan et al.
patent: 5286895 (1994-02-01), Singh
patent: 5498536 (1996-03-01), Khandke
patent: 5545625 (1996-08-01), Gross et al.
patent: 5658889 (1997-08-01), Gruber et al.
patent: 5695761 (1997-12-01), Denhardt et al.
patent: 5730992 (1998-03-01), Savion et al.
patent: 5912019 (1999-06-01), Singh
patent: 5965553 (1999-10-01), Bell et al.
patent: 5968983 (1999-10-01), Kaesemeyer
patent: 6080778 (2000-06-01), Yankner et al.
patent: 6147109 (2000-11-01), Liao et al.
patent: 6204248 (2001-03-01), Demopoulos et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6511800 (2003-01-01), Singh
patent: 6552075 (2003-04-01), Gribble et al.
patent: 6605729 (2003-08-01), Byrn et al.
patent: 6673831 (2004-01-01), Tobert
patent: 7049058 (2006-05-01), Singh
patent: WO 93/14749 (1993-08-01), None
patent: WO 95/06470 (1995-03-01), None
patent: WO 98/09653 (1998-03-01), None
patent: WO 02/24194 (2002-03-01), None
Boese M. et al. Effect of cGMP Dependent Vasodilators on the Expression of Inducible Nitric Oxide Synthase in Vascular Smooth Muscle Cells. British J of Pharmacology 1996 119(4)707-715.
Sherman M. et al. Pyrrolidine Dithiocarbamate Inhibits Induction of Nitric Oxide Synthase Activity in Rat Alveolar Macrophages. Biochemical and Biophysical Research Communications 1993 191(3)1301-1308.
Pahan, K. et al. Increasing cAMP Attenuates Induction of iNOS in Rat Primary Astrocytes. J of Biological Chemistry Mar. 1997 272(12)7786-7791.
Paul et al. Differential Regulation by Protein Kinase C . . . British J of Pharm 120:940-946, 1997.
Hadjidakis D. et al. The Antidiabetic Action of Somatostatin-28 . . . Hormone and Metabolic Research. Nov. 1987 19(11)574-8.
Eizrik D. et al. The Inducible Form of Nitric Oxide Synthase in Insulin Producing Cells. Diabete & Metabolisme (Paris) 1994 20(2)116-122.
Parving H. Cholesterol Lowering Therapy May Retard the Progression of Diabetic Nephropathy. Diabetologia 1996 39, 367-373.
“Nymox pursuing new approaches to fighting Alzheimer's disease,”Business Wire, Jul. 2, 2004.
“Statins-the next miracle drug? Beyond cholesterol lowering,”Clinician Reviews, 14(6):84(3), Jun. 1, 2004.
Amerongen et al., “Simvastatin improves disturbed endothelial barrier function,”Circulation, 102:2803-2809, 2000.
Baughman, “Dopamine-transporter density in patients with ADHD,”The Lancet, 355:1460-61, 2000.
Bedoya et al., “Pyrrolidine dithiocarbamate prevents IL-1-induced nitric oxide synthase mRNA, but not superoxide dismutase mRNA, in insulin producing cells,”Biochemical and Biophysical Research Communications, 210:816-822, 1995.
Bellosta et al., “Direct vascular effects of HMG-CoA reductase inhibitors,”Atheroscl., 137:S101-109, 1998.
Bellosta et al., “Non-lipid related effects of statins,”Ann. Med., 32:164-176, 2000.
Boese, “Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP,”British J of Pharmacology, 119:707-715, 1996.
Bowen and Guyton, “Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol,”Current Science, 2:58-63, 2000.
Buemi et al., “Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy,”Clin. Phar.&Therapeutics, 67:427-431, 2000.
Casey et al., “p21ras is modified by a farnesyl isoprenoid,”Proc. Natl. Acad. Sci., 86:8323-27, 1989.
Corsini et al., “Non-lipid -related effects of 3-hydroxy-3-methylgluataryl coenzyme A reductase inhibitors,”Cardiology, 87:458-468, 1996.
Cuzzocrea et al., “Beneficial effects of n-acetylcysteine on ischemic brain injury,”British Journal of Pharmacology, 130:1219-1226, 2000.
Duval, “Effects of statins on ischemic stroke: neuroprotection and/or triggering of apototic damage?”Letters to the Editor, p. 989-990, no date given.
Faggioto and Paoletti, “Statins and blockers of the renin-agiotensin system: vascular protection beyond their primary mode of action,”Hypertension, 34:987-996, 1999.
Farmer, “Pleiotropic effects of statins,”Curr. Atheroscl. Rpts., 2:208-217, 2000.
Fenyk-Melody et al., “Experimental autoimmune encephalomyelitis is exacerbated in mice lacking theNOS2gene,”J of Immunology 160:2940-2946, 1998.
Frances et al., “Outcome of kidney transplant recipients with previous human herpesvirus-8 infection,”Transplantation, 69:1776-1779, 2000.
Fukuo et al., “Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages,”J. Nippon Med. Sch., 62:74-78, 1995.
Fukuzawa et al., “N-acetylcysteine ameliorates reperfusion injury after warm hepatic ischemia,”Transplantation, 5(1):6-9, 1995.
Galinanes et al., “Sustained protection by acadesine against ischemia- and reperfusion-induced injury: Studies in the transplanted rat heart,”Circulation,86(2):589-611, 1992.
Giri et al., “5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase,”J. Neuroscience, 24(2):479-487, 2004.
Grip et al., “Pravastatin down-regulates inflammatory mediators in human monocytes in vitro,”Eur. J. Pharmacol., 410:83-92, 2000.
Hashimoto et al., “5-amino-4-imidazolecarboxamide riboside confers strong tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent fashion,”Biochemical and Biophysical Research Communications, 290:263-267, 2002.
Hibbs et al., “Evidence for cytokine-inducible nitric oxide synthesis from l-arginine in patients receiving interleukin-2 therapy,”J. Clin. Invest., 89:867-877, 1992.
Horwich et al., “Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure,”J. Am. College of Cardiol., 43(4):642-548, 2004.
Ikeda and Shumada, “Statins and monocytes,”The Lancet, 353:2070, 1999.
Inoue et al., “Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2 and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in preimary endothelial cells,”Life Sciences, 67:863-876, 2000.
Issazadeh et al., “Interferon γ, interleukin 4 and transforming growth factor β in experimental autoimmune encephalomyelitis in lewis rats: dynamics of cellular MRNA expression in the central nervous system and lymphoid cells.,”J. Neuroscience. Res., 40:579-590, 1995.
Izzat et al., “New molecular targets for cholesterol-lowering therapy,”J. Pharmacol.&Exp. Therapeutics, 293:315-320, 2000.
Johnson, “Multi-Purpose Medicine,” http://my.abcnews.go.com 2000.
Josefsen, “Statins may reduce risk of Alzheimer's disease,”BMJ, 321:28, 2000.
Jukema et al., “Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels,”Circulation, 91:2528-2540, 1995.
Katznelson et al., “The effect of pravastatin on acute rejection after kidney transplantation—a pilot study,”Transplantation, 61:1469-1474, 1996.
Knuckey et al., “N-acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats,&#x
Fulbright & Jaworski L.L.P.
Gitomer Ralph
Musc Foundation for Research Development
LandOfFree
Inhibitors of nitric oxide synthase to treat type 1 diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of nitric oxide synthase to treat type 1 diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of nitric oxide synthase to treat type 1 diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3964196